HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

purvalanol B

protein kinase inhibitor; structure in first source

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Adenine: 2120
        purvalanol B: 3

Experts

1.	Albanese, Chris: 3 articles (11/2014 - 08/2010)
2.	Ringer, Lymor: 3 articles (11/2014 - 08/2010)
3.	Rodriguez, Olga: 3 articles (11/2014 - 08/2010)
4.	Sirajuddin, Paul: 3 articles (11/2014 - 08/2010)
5.	Avantaggiati, Maria Laura: 2 articles (11/2014 - 08/2010)
6.	Heckler, Mary: 2 articles (11/2014 - 11/2011)
7.	Schlegel, Richard: 2 articles (11/2014 - 11/2011)
8.	Brown, Milton L: 2 articles (11/2011 - 08/2010)
9.	Ghosh, Anup: 2 articles (11/2011 - 08/2010)
10.	Abdelgawad, Iman: 1 article (11/2014)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 08/15/2010 - "Our results demonstrate that VMY-1-103 was more effective in inducing apoptosis in PCa cells than its parent compound, purvalanol B, and support the testing of VMY-1-103 as a potential small molecule inhibitor of prostate cancer in vivo." 08/15/2010 - "VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells."
2.	Breast Neoplasms (Breast Cancer) 11/01/2011 - "VMY-1-103, a novel dansylated analog of purvalanol B, was previously shown to inhibit cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B. " 08/15/2010 - "We have recently designed and synthesized a novel dansylated analog of purvalanol B, termed VMY-1-103, that inhibited cell cycle progression in breast cancer cell lines more effectively than did purvalanol B and allowed for uptake analyses by fluorescence microscopy. "
3.	Neoplasms (Cancer) 11/15/2014 - "VMY-1-103 (VMY), a dansylated analog of purvalanol B, displays rapid and potent anti-tumor activities, however the pathways by which VMY works are not fully defined. "

Related Drugs and Biologics

1.	2- chloro- N- (2- (5- (dimethylamino)naphthalene- 1- sulfonamido)ethyl)- 4- (2- (1- hydroxy- 3- methylbutan- 2- ylamino)- 9- isopropyl- 9H- purin- 6- ylamino)benzamide